Alvaro Amorrortu, MBA, MS

Prior to Mediphage, Alvaro was the COO of Solid Biosciences, a Cambridge-based company working on a gene therapy approach to treat Duchenne Muscular Dystrophy. At Solid, he was responsible for building and supporting the infrastructure to enable the execution of Solid’s programs, including managing the relationships with CDMOs and overseeing Process Development efforts. Alvaro spent more than a decade as a management consultant advising biopharmaceutical and other companies on a variety of strategic challenges, including supervising large-scale organizational transformations as well as designing strategies for assets and portfolios moving from early stages of development to commercial launch. He started his strategist career at the Monitor Group, and after a few years working for Inventiv Health (now Syneos Health), moved to IMS Health (now IQVIA).